<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fever and rash in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fever and rash in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fever and rash in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fred A Lopez, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles V Sanders, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul E Sax, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 17, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before the introduction of effective combination antiretroviral therapy, dermatologic manifestations affected up to 80 to 90 percent of individuals infected with the human immunodeficiency virus (HIV) [
         <a href="#rid1">
          1-4
         </a>
         ]. The frequency of cutaneous manifestations was illustrated in a review of 684 patients with HIV who were followed for almost three years; 540 patients (79 percent) were given one or more (average 3.7) dermatologic diagnoses [
         <a href="#rid3">
          3,5
         </a>
         ]. Importantly, a higher number of mucocutaneous diseases in patients with HIV has been shown to correlate with poor prognosis and a shorter time to the development of AIDS [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Rash can occur as a manifestation of HIV infection, another infection, some neoplasms, and frequently as a reaction to a drug. The defect in cell-mediated immunity that results from HIV infection predisposes infected individuals to certain bacterial, fungal, mycobacterial, and viral infections, many of which have skin manifestations. In addition, many immune reconstitution inflammatory syndrome-associated events are dermatological and warrant consideration in the individual with HIV who has recently started highly active antiretroviral therapy [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Characteristic fever and rash syndromes in the patient with HIV will be reviewed here. Recognition of these syndromes may allow for earlier detection of HIV infection and the salutary effects of initiating antiretroviral therapy.
        </p>
        <p>
         The diagnosis and treatment of the individual diseases as well as the epidemiology, etiology, and diagnostic approach to fever and rash in immunocompromised hosts without HIV and in normal hosts are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1409.html" rel="external">
          "Fever and rash in immunocompromised patients without HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2744.html" rel="external">
          "Fever and rash in the immunocompetent patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          BACTERIAL INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection have an increased incidence of bacterial infections, which is related to both deficiencies in T-cell function and dysregulation of humoral immunity in advanced disease. Risk factors associated with the development of skin and soft tissue infections in outpatients with HIV include the presence of certain comorbid conditions (eg, diabetes, psoriasis, and lymphedema), as well as an HIV viral load greater than 1000 copies/mL and the presence of an intravenous catheter [
         <a href="#rid10">
          10
         </a>
         ]. However, the incidence of skin and soft tissue infections in persons with HIV appears to be decreasing. In one report that evaluated the rate of skin and soft tissue infections in patients with HIV who were seen in United States-based emergency departments, the incidence decreased by approximately 15 percent between 2009 and 2014 [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Staphylococcus aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Staphylococcus aureus
         </em>
         is a common cause of skin infection and bacteremia in patients with the acquired immunodeficiency syndrome (AIDS). Risk factors for
         <em>
          S. aureus
         </em>
         bacteremia include nasal colonization with
         <em>
          S. aureus
         </em>
         , injection drug use (IDU), lymphedema due to Kaposi sarcoma (KS), neutropenia, and indwelling vascular catheters [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Colonization with
         <em>
          S. aureus
         </em>
         is increased in individuals with HIV, and an increasing number of isolates are methicillin-resistant [
         <a href="#rid13">
          13-17
         </a>
         ]. Risk factors for methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) include the following: history of prior MRSA infection; recent systemic antibiotic use or hospitalization (ie, within last six months); lower CD4 count; recent sexually transmitted infection; and prior incarceration [
         <a href="#rid18">
          18-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology"
         </a>
         .)
        </p>
        <p>
         HIV infection also appears to increase the risk for community-associated MRSA skin and soft tissue infections and subsequent recurrences [
         <a href="#rid24">
          24,25
         </a>
         ]. In one retrospective cohort study, almost one-third of patients with HIV experienced a recurrent episode of skin and soft tissue infections within the following year [
         <a href="#rid26">
          26
         </a>
         ]. HIV infection is also an independent risk factor for recurrence of infection due to
         <em>
          S. aureus
         </em>
         in patients with a history of
         <em>
          S. aureus
         </em>
         bacteremia [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The varied skin manifestations of
         <em>
          S. aureus
         </em>
         infection include impetigo, ecthyma, folliculitis, cellulitis, abscesses/furuncles, plaques, ulcerations, or ecthyma gangrenosum  (
         <a class="graphic graphic_picture graphicRef63238" href="/z/d/graphic/63238.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef75659" href="/z/d/graphic/75659.html" rel="external">
          picture 2
         </a>
         ). Progression of staphylococcal infections can lead to cutaneous botryomycosis, a plaque-like, nodular, or papular lesion that clinically resembles a fungal infection and is characterized by aggregates of bacteria in the skin [
         <a href="#rid28">
          28,29
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7649.html" rel="external">
          "Botryomycosis"
         </a>
         ). Secondary staphylococcal infections of underlying skin disorders such as herpetic ulcers, abrasions/trauma, eczema, adverse cutaneous drug eruptions, and other dermatoses should also be considered.
        </p>
        <p>
         Therapy with antibiotics and debridement or drainage, when indicated, is imperative because these sites can serve as portals of entry for disseminated disease. (See
         <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">
          "Impetigo"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">
          "Infectious folliculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">
          "Acute cellulitis and erysipelas in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Bacillary angiomatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacillary angiomatosis, a vascular skin lesion that can mimic several other conditions (eg, KS  (
         <a class="graphic graphic_picture graphicRef76323" href="/z/d/graphic/76323.html" rel="external">
          picture 3
         </a>
         ), pyogenic granuloma, cherry angioma, dermatofibroma, hemangioma, and verruga peruana), is usually seen in patients with HIV when the CD4 cell count is less than 100 cells/microL. These cutaneous lesions result from proliferation of small blood vessels. The etiologic agents of this disease,
         <em>
          Bartonella henselae
         </em>
         and
         <em>
          Bartonella quintana
         </em>
         , can also cause bloodstream, liver, lymph node, lung, bone, bone marrow, brain, and heart valve infection. Cat exposure has been associated with
         <em>
          B. henselae
         </em>
         infections and body louse exposure with
         <em>
          B. quintana
         </em>
         .
        </p>
        <p>
         The skin lesions associated with
         <em>
          Bartonella
         </em>
         , which may be isolated or multiple, are typically hemangiomatous, small, and papular before becoming larger, nodular, and potentially friable with trauma-associated bleeding. Occasional lesions are subcutaneous in location (with or without overlying erythema) and appear cyst-like or manifest as a small tumor-like mass. Ulcerative lesions have also been described [
         <a href="#rid30">
          30
         </a>
         ]. Intermittent fever is often associated with
         <em>
          Bartonella
         </em>
         bacteremia and should be considered in patients with AIDS and fever of unknown origin [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5512.html" rel="external">
          "Bartonella infections in people with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Neisseria gonorrhoeae
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV have an increased rate of gonococcal infection that is related more to sexual behavior than to immunosuppression. Fever, rash, tenosynovitis, and polyarthralgia are typically part of disseminated gonococcal infection (DGI). The rash typically consists of painless lesions, often between two and ten in number, often located over trunk, extremities, or soles/palms. The lesions are usually pustular or vesiculopustular, although hemorrhagic macules, papules, or nodules rarely occur  (
         <a class="graphic graphic_picture graphicRef71303" href="/z/d/graphic/71303.html" rel="external">
          picture 4
         </a>
         ). Pustular or vesicular skin lesions are often transient and, even without treatment, may only last for three to four days. (See
         <a class="medical medical_review" href="/z/d/html/7603.html" rel="external">
          "Disseminated gonococcal infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Syphilis is important to recognize because of its important public health implications, including its association with increased HIV acquisition and seroprevalence [
         <a href="#rid32">
          32,33
         </a>
         ]. The skin manifestations of syphilis are often an important diagnostic clue, although persons with HIV who have repeat syphilis infection are more likely to be asymptomatic (or at least less symptomatic) than during initial infection [
         <a href="#rid34">
          34,35
         </a>
         ]. When skin lesions are present, they usually present in a manner similar to individuals without HIV; however, some clinical manifestations may be altered in the setting of HIV infection [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Primary syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first, or primary stage of syphilis, presents as a chancre usually two to three weeks after sexual contact with an infected partner. A painless papule forms at the mucosal surface where
         <em>
          Treponema pallidum
         </em>
         , the causative agent of syphilis, was inoculated  (
         <a class="graphic graphic_picture graphicRef75291" href="/z/d/graphic/75291.html" rel="external">
          picture 5
         </a>
         ). The papule can grow to 0.5 to 2 cm in diameter, and ulcerate to form a clean-based, well-demarcated lesion with firm and indurated margins. Associated non-tender regional lymph nodes are often seen. Although chancres are usually solitary, multiple chancres can occur, particularly in the setting of HIV infection [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">
          "Syphilis in patients with HIV", section on 'Early syphilis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Secondary syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rash is the most characteristic finding in secondary syphilis, occurring in more than 80 percent of patients. Secondary syphilis occurs three to six weeks after the primary stage resolves and is characterized by hematogenous dissemination of treponemes. Additional symptoms and signs include malaise, low grade fever, sore throat, lymphadenopathy, alopecia, arthralgias, and headache.
        </p>
        <p>
         Skin manifestations of secondary syphilis can present in a variety of forms (ie, "the great imitator") including a nonpruritic macular, maculopapular, papular, papulosquamous, nodular, erythroderma, plaque-like, erythema multiforme-like or pustular rash; vesicular lesions are notably absent. The anogenital region and other moist intertriginous areas may contain condylomata lata, wart-like lesions consisting of flat eroded papules. Mucous patches consisting of slightly raised grayish-white painless ulcerations may be seen on mucous membranes. An uncommon but severe nodular-ulcerative presentation of secondary syphilis known as lues maligna has also been reported in patients with HIV infection [
         <a href="#rid40">
          40
         </a>
         ]. The rash usually begins on the trunk and extremities. When lesions are seen on the palms and soles, secondary syphilis should be strongly considered  (
         <a class="graphic graphic_picture graphicRef68877" href="/z/d/graphic/68877.html" rel="external">
          picture 6
         </a>
         ). Hair loss with a patchy "moth-eaten" appearance may also be seen.
        </p>
        <p>
         In most patients with syphilis, the primary chancre resolves prior to the presentation of secondary syphilis. However, overlap of the primary and secondary stages of syphilis has been reported in patients with HIV (9 of 21 in one report) [
         <a href="#rid41">
          41,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">
          "Syphilis in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Tertiary syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gummatous lesions of late benign syphilis can involve any organ, including the skin. Often solitary, gummas can present as ulcerative, nodular, or papulosquamous lesions, usually located over the trunk, extremities, and face. Patients with HIV are reported to have a shorter interval to the development of destructive localized gummatous lesions than HIV-seronegative patients [
         <a href="#rid39">
          39,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">
          "Syphilis in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Pneumococcus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of HIV infection substantially increases the risk of invasive pneumococcal infection, particularly when the CD4 count is less than 200 cells/microL [
         <a href="#rid44">
          44-48
         </a>
         ]. Skin manifestations of disseminated pneumococcal infection can include cellulitis and purpura fulminans  (
         <a class="graphic graphic_picture graphicRef63897" href="/z/d/graphic/63897.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         The incidence of bacteremic pneumococcal disease appears to be decreasing with the use of combination antiretroviral therapy [
         <a href="#rid51">
          51,52
         </a>
         ]. A decrease has also been noted in adults with HIV since the introduction of the pneumococcal conjugate vaccine for children [
         <a href="#rid53">
          53
         </a>
         ]. Since 2012, the use of both pneumococcal conjugate vaccine and
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         are recommended for individuals &gt;19 years of age with HIV. (See
         <a class="medical medical_review" href="/z/d/html/85526.html" rel="external">
          "Pneumococcal immunization in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Helicobacter cinaedi
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Helicobacter cinaedi
         </em>
         , a gram-negative spiral-shaped bacillus, can cause (recurrent) cellulitis or erythema nodosum-like lesions, fever, arthritis, and bacteremia in patients with HIV [
         <a href="#rid54">
          54-57
         </a>
         ]. The organism is fastidious and requires special growth conditions. Thus, this infection may be missed if the laboratory is not notified.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MYCOBACTERIAL INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous disease may be a clue to underlying disseminated mycobacterial infection. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tuberculosis
         </strong>
         – The cutaneous manifestations of tuberculous include scrofuloderma (contiguous spread from a deep structure such as lymph node, bone, or joint to overlying skin, leading to a draining, suppurative, nodular process); gummatous lesions (metastatic tuberculous abscesses due to hematogenous spread that progress to draining sinuses and ulcerations); lupus vulgaris (brownish-red papules/plaques involving head, neck, lower extremities, or buttocks, resulting from contiguous infection or hematogenous/lymphatic spread); and pustules [
         <a href="#rid58">
          58
         </a>
         ]. Cutaneous miliary tuberculosis, an unusual manifestation of hematogenous dissemination, has been reported in patients with HIV, particularly when the CD4 count is low [
         <a href="#rid59">
          59-62
         </a>
         ]. Initial lesions are papulopustular, macular, and/or vesicular before becoming ulcerative. Microscopic examination of the skin lesions will demonstrate numerous acid-fast bacilli. (See
         <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">
          "Cutaneous manifestations of tuberculosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical mycobacteria
         </strong>
         – Atypical mycobacteria, including
         <em>
          Mycobacterium avium
         </em>
         <em>
          intracellulare
         </em>
         and
         <em>
          Mycobacterium kansasii
         </em>
         , may also present as isolated cutaneous disease [
         <a href="#rid63">
          63-65
         </a>
         ].
         <em>
          Mycobacterium haemophilum
         </em>
         , an uncommon cause of mycobacterial infections, primarily presents as cutaneous or subcutaneous disease in the setting of immunocompromise [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3705.html" rel="external">
          "Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3755.html" rel="external">
          "Mycobacterium avium complex (MAC) infections in persons with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Lesions associated with mycobacterial infections are polymorphous, highlighting the need to isolate the etiologic agent in culture in order to direct therapy [
         <a href="#rid67">
          67-69
         </a>
         ]. Mycobacterial-associated immune reconstitution inflammatory syndrome may also present with cutaneous manifestations [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          VIRAL INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin lesions due to viral infections are common in patients with HIV, and include acute HIV infection itself. Since many of these viral infections are vaccine-preventable, a thorough vaccination history should be obtained. (See
         <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">
          "Immunizations in persons with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Acute HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin rash can be one manifestation of the acute retroviral syndrome, a mononucleosis- or flu-like syndrome that occurs after primary HIV infection in up to 75 percent of cases [
         <a href="#rid72">
          72
         </a>
         ]. Additional signs and symptoms include fever, night sweats, fatigue, malaise, generalized lymphadenopathy, sore throat, arthralgias, myalgias, headache, nausea/vomiting, and diarrhea [
         <a href="#rid73">
          73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">
          "Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         A generalized skin eruption typically occurs 48 to 72 hours after the onset of fever and persists for five to eight days. The upper thorax, neck, and face are most often involved though the scalp and extremities, including the palms and soles, may be affected. The lesions are characteristically small (5 to 10 mm), well-circumscribed, oval or round, pink to deeply red colored macules or maculopapules [
         <a href="#rid75">
          75
         </a>
         ]. Vesicular, pustular, and urticarial eruptions have also been reported [
         <a href="#rid74">
          74,76
         </a>
         ] but are not nearly as common as a maculopapular rash. Pruritus is unusual and only mild when present. Oropharyngeal enanthems and ulcerations, as well as anogenital ulcerations can occur [
         <a href="#rid75">
          75,77
         </a>
         ].
        </p>
        <p>
         Acute HIV infection should be considered in the differential diagnosis of a patient presenting with a mononucleosis-like illness. In a retrospective study of 563 serum samples obtained from patients with suspected mono-like illness with negative heterophile antibody tests, 11 (2 percent) were positive for HIV-1 RNA and four had greater than 100,000 copies/mL of HIV-1 viral RNA, consistent with acute HIV-1 infection [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis", section on 'Primary HIV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Genital herpes virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary episode of genital herpes simplex virus (HSV) infection usually presents with fever, headache, and malaise, in association with localized symptoms of pain and pruritus in the area of the vesicular lesions. However, most genital HSV infections occurring in patients with HIV reflect reactivation syndromes, and the appearance of lesions is usually not accompanied by fever. Rates of reactivation appear to be inversely correlated with CD4 counts [
         <a href="#rid79">
          79
         </a>
         ]. In addition, immune reconstitution inflammatory syndrome (IRIS)-associated events involving genital herpes virus infection appear to be more common than other manifestations [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"
         </a>
         .)
        </p>
        <p>
         The clinical presentation of symptomatic HSV episodes may include extensive mucocutaneous involvement, a variable appearance of genital lesions, and the development of chronic nonhealing and recurrent ulcers. Tumor-like, deep ulcerative, and hypertrophic lesions have also been reported [
         <a href="#rid80">
          80
         </a>
         ]. Recurrences are often more frequent, more extensive, and of longer duration than in immunocompetent patients  (
         <a class="graphic graphic_picture graphicRef59219 graphicRef72032 graphicRef55663" href="/z/d/graphic/59219.html" rel="external">
          picture 8A-C
         </a>
         ).
        </p>
        <p>
         Of note, herpes simplex virus type 2 infections may increase the risk of HIV acquisition [
         <a href="#rid81">
          81-86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Varicella-zoster virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of herpes zoster (HZ) (including recurrent HZ) is higher in patients with HIV compared with those without concomitant HIV, with recurrent HZ being reported in up to 20 percent of HIV infected patients [
         <a href="#rid87">
          87-89
         </a>
         ]. In general, the risk of HZ increases as CD4 cell counts fall [
         <a href="#rid90">
          90,91
         </a>
         ], while the use of effective combination antiretroviral therapy decreases the risk of HZ [
         <a href="#rid92">
          92
         </a>
         ]. However, an increased frequency of varicella-zoster virus (VZV) reactivation can be seen during immune recovery following initiation of ART [
         <a href="#rid8">
          8,70,93,94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'HIV infection'
         </a>
         .)
        </p>
        <p>
         Like HSV infections, chronic (ie, greater than one month) mucocutaneous infections with VZV are well described in individuals with HIV [
         <a href="#rid95">
          95
         </a>
         ]. Atypical presentations of HZ also include verrucous varicella, which has been mainly reported in the setting of HIV infection [
         <a href="#rid91">
          91,96
         </a>
         ]. This diagnosis should be considered in the patient with multiple, chronic, wart-like lesions [
         <a href="#rid96">
          96,97
         </a>
         ]. Bullous, necrotic, and hemorrhagic lesions have also been described.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Parvovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus B19 can cause fever, arthralgia and a lacy reticular rash on the trunk and extremities in both immunocompetent and immunocompromised individuals. Cutaneous vasculitis due to human parvovirus B19 has also been reported [
         <a href="#rid98">
          98
         </a>
         ]. However, in the setting of HIV, severe, chronic anemia with reticulocytopenia may persist due to impaired humoral responses in those with advanced immunosuppression [
         <a href="#rid99">
          99,100
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Hepatitis B
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of shared routes of transmission, patients with HIV may also acquire hepatitis B virus through unprotected intercourse with a chronically infected partner or through injection drug use [
         <a href="#rid101">
          101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection"
         </a>
         .)
        </p>
        <p>
         Acute hepatitis B infection may be heralded by a serum sickness-like syndrome, manifested as fever, skin rash (including urticaria), arthralgia and arthritis, which usually subsides with the onset of jaundice. Chronic hepatitis B virus infection can be associated with the development of polyarteritis nodosa, and skin lesions may include palpable purpura or livedo reticularis. (See
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Skin disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          FUNGAL INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin lesions may be the initial sign of a systemic fungal infection. Endemic fungi must be considered in any patient with HIV, skin lesions, and systemic disease. Fungi can disseminate when cell-mediated immunity falls, either during the acute stage of infection or as a result of reactivation of prior disease [
         <a href="#rid102">
          102-105
         </a>
         ]. Patients with HIV may harbor more than one fungus responsible for systemic infection and associated cutaneous manifestations, underscoring the importance of histopathologic and microbiologic evaluation of suspicious skin lesions [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Cryptococcosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Cryptococcus neoformans
         </em>
         is an encapsulated yeast that is found worldwide. It is a common opportunistic infection in immunosuppressed patients with AIDS, particularly when the CD4 count is &lt;100 cells/microL.
        </p>
        <p>
         Approximately 10 percent of patients with HIV who develop cryptococcal infection have cutaneous manifestations of disease [
         <a href="#rid107">
          107
         </a>
         ]. Skin lesions secondary to
         <em>
          C. neoformans
         </em>
         may represent the sentinel clue to underlying disseminated infection.
        </p>
        <p>
         The skin lesions of cryptococcosis may be quite diverse, but ulcers, nodules, papules, pustules, or molluscum contagiosum-like centrally umbilicated vesicular lesions are commonly described  (
         <a class="graphic graphic_picture graphicRef52777" href="/z/d/graphic/52777.html" rel="external">
          picture 9
         </a>
         ). Presentations can also mimic cellulitis or cutaneous malignancies such as basal cell or squamous cell carcinoma(s). Lesions are frequently located on the head and neck [
         <a href="#rid108">
          108
         </a>
         ]. Since cryptococcal skin infection can mimic molluscum contagiosum, a helpful diagnostic clue for cryptococcosis is the finding of a small hemorrhagic center in the lesion and a rapid onset of development of the papules  (
         <a class="graphic graphic_picture graphicRef69214" href="/z/d/graphic/69214.html" rel="external">
          picture 10
         </a>
         ) [
         <a href="#rid109">
          109
         </a>
         ]. Cryptococcal-associated immune reconstitution inflammatory syndrome (IRIS) has been reported and commonly includes lymphadenitis [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Histoplasmosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histoplasmosis is a dimorphic fungus concentrated in the Ohio and Mississippi River valleys in the United States. It is also found in the Caribbean, Central America, South America, Cuba, Southeast Asia, and Africa.
        </p>
        <p>
         Patients with HIV can acquire primary histoplasmosis infection when visiting areas of endemicity, or can develop reactivation disease many years later, particularly in the setting of advanced immunosuppression [
         <a href="#rid111">
          111
         </a>
         ]. Skin lesions appear to be more common in patients with disseminated histoplasmosis who have acquired immunodeficiency syndrome when compared to those not coinfected with human immunodeficiency virus [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         Approximately 10 percent of patients with HIV and disseminated histoplasmosis have mucocutaneous manifestations including oropharyngeal ulcerations, macules, papules, pustules, plaques (can be verrucous), nodules, necrosis, or vesicles [
         <a href="#rid113">
          113,114
         </a>
         ]  (
         <a class="graphic graphic_picture graphicRef67641 graphicRef68101" href="/z/d/graphic/67641.html" rel="external">
          picture 11A-B
         </a>
         ). Cutaneous histoplasmosis can mimic erythema-multiforme, molluscum contagiosum, pyoderma gangrenosum, vasculitic, exfoliative dermatitis, herpetic, acneiform, and psoriatic-like lesions  (
         <a class="graphic graphic_picture graphicRef74799 graphicRef67381" href="/z/d/graphic/74799.html" rel="external">
          picture 12A-B
         </a>
         ) [
         <a href="#rid113">
          113-116
         </a>
         ]. Lesions are commonly located over the face, chest, and extremities. A
         <em>
          Histoplasma
         </em>
         -associated IRIS involving the skin has also been reported [
         <a href="#rid117">
          117,118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">
          "Pathogenesis and clinical manifestations of disseminated histoplasmosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Blastomycosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Blastomyces dermatitidis
         </em>
         is a dimorphic fungus seen in the south-central and Midwestern United States, northern New York, the southeastern provinces of Canada, and Africa. Blastomycosis can present with severe disseminated disease (including central nervous system involvement), usually in the setting of advanced immunosuppression [
         <a href="#rid119">
          119,120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2437.html" rel="external">
          "Clinical manifestations and diagnosis of blastomycosis", section on 'Extrapulmonary blastomycosis'
         </a>
         .)
        </p>
        <p>
         The skin is the most common site of extrapulmonary involvement, and possible dermatologic manifestations of blastomycosis include papules, pustules, ulcers, subcutaneous nodules, cold abscesses, or verrucoid lesions  (
         <a class="graphic graphic_picture graphicRef78481 graphicRef71630" href="/z/d/graphic/78481.html" rel="external">
          picture 13A-B
         </a>
         ) [
         <a href="#rid119">
          119,120
         </a>
         ]. A retrospective survey of 15 patients with HIV and blastomycosis included eight patients with disseminated disease [
         <a href="#rid119">
          119
         </a>
         ]. All of these individuals had CD4 counts below 200 cells/microL, and three had evidence of cutaneous disease.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Coccidioidomycosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dimorphic fungus
         <em>
          Coccidioides immitis
         </em>
         is endemic in the southwestern United States, including California, Arizona, New Mexico, Utah, Nevada, and Texas, and also in Mexico and Central and South America (particularly Argentina). A prospective study of patients with HIV in a highly endemic area in Arizona reported the development of active coccidioidal infection in approximately 25 percent of this cohort during 3.5 years of follow-up [
         <a href="#rid121">
          121
         </a>
         ]. In another analysis, one percent of AIDS patients residing in counties of the United States endemic for this fungus had coccidioidomycosis [
         <a href="#rid122">
          122
         </a>
         ]. Subsequent data after the introduction of combination ART described a decrease in the severity and incidence of symptomatic coccidioidal infections in a coccidioidomycosis-endemic area [
         <a href="#rid123">
          123
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">
          "Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"
         </a>
         .)
        </p>
        <p>
         Hematogenous dissemination of this organism can manifest cutaneously. Skin lesions in this disease may take many forms, including pustules, nodules, ulcers, verrucous plaques, and erythematous papules; though nonspecific, these lesions are usually hemorrhagic [
         <a href="#rid124">
          124
         </a>
         ]  (
         <a class="graphic graphic_picture graphicRef78978" href="/z/d/graphic/78978.html" rel="external">
          picture 14
         </a>
         ). A thorough travel history should be obtained, since presentations of fungal disease may be due to reactivation of prior infection. Of note in one report of persons with AIDS and disseminated coccidioidomycosis, only about one-half of all cases resided in
         <em>
          C. immitis
         </em>
         -endemic countries [
         <a href="#rid122">
          122
         </a>
         ]. Disseminated coccidioidomycosis with cutaneous lesions as a manifestation of IRIS has also been reported [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Sporotrichosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Sporothrix schenckii
         </em>
         is a dimorphic fungus that is ubiquitous in warmer areas of the world. Cutaneous manifestations of infection may occur from direct inoculation through the skin as a localized, lymphocutaneous infection, classically following trauma involving a rose thorn or soil. Less commonly, sporotrichosis presents with extensive cutaneous involvement (ulcerated and crusted nodules) in patients with advanced AIDS consistent with underlying disseminated disease  (
         <a class="graphic graphic_picture graphicRef67553" href="/z/d/graphic/67553.html" rel="external">
          picture 15
         </a>
         ) [
         <a href="#rid126">
          126-128
         </a>
         ]. These atypical ulcerations are often described as "punched-out" [
         <a href="#rid129">
          129
         </a>
         ]. Following dissemination, bone or joint infection can occur. Disseminated sporotrichosis with skin lesions as a manifestation of IRIS has been reported [
         <a href="#rid130">
          130
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2457.html" rel="external">
          "Clinical features and diagnosis of sporotrichosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Talaromyces (formerly Penicillium) marneffei
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Talaromyces
         </em>
         (formerly
         <em>
          Penicillium
         </em>
         )
         <em>
          marneffei
         </em>
         is an endemic dimorphic fungal pathogen in Southeast Asia, northeastern India, and southern China [
         <a href="#rid131">
          131-133
         </a>
         ]. The clinical presentation often includes weight loss, fever, skin lesions, respiratory symptoms, peripheral lymphadenopathy, transaminitis, and anemia. Disseminated disease usually occurs when the CD4 cell count is less than 50 to 100 cells/microL and most commonly involves the skin, blood, bone marrow, lymph nodes, liver, and lungs [
         <a href="#rid134">
          134,135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection"
         </a>
         .)
        </p>
        <p>
         Papular skin lesions, often with central umbilication, are typically located on the trunk and face and may resemble molluscum contagiosum  (
         <a class="graphic graphic_picture graphicRef62477" href="/z/d/graphic/62477.html" rel="external">
          picture 16
         </a>
         ). Genital and oral ulcerations have also been reported [
         <a href="#rid136">
          136,137
         </a>
         ]. Disseminated
         <em>
          T. marneffei
         </em>
         infection with skin involvement can be seen as a manifestation of IRIS [
         <a href="#rid138">
          138,139
         </a>
         ].
        </p>
        <p>
         In one series of 80 patients with HIV in Thailand with disseminated
         <em>
          T. marneffei
         </em>
         infection, 71 percent had skin lesions [
         <a href="#rid140">
          140
         </a>
         ]. In another series of 46 patients in India, skin lesions were reported in 81 percent of cases [
         <a href="#rid141">
          141
         </a>
         ]. A series of 127 patients from northern Vietnam reported skin lesions in 83 percent of cases [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H278478407">
         <span class="h2">
          Emergomyces (formerly Emmonsia) species
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Emergomyces
         </em>
         (formerly
         <em>
          Emmonsia
         </em>
         ) species are dimorphic fungi that can cause human disease. In South Africa,
         <em>
          Emergomyces africanus
         </em>
         is the most common endemic mycosis and has been reported to cause disseminated infection in patients with HIV and low CD4 counts (usually &lt;100 cells/microL) [
         <a href="#rid143">
          143,144
         </a>
         ]. Clinical findings typically include fever, weight loss, anemia, elevated liver function tests, and chest radiographic findings that mimic
         <em>
          Mycobacterium tuberculosis
         </em>
         .
        </p>
        <p>
         Dermatologic manifestations, seen in most patients with disseminated infection, include papules, plaques, and ulcers, similar to those lesions seen in other disseminated fungal infections, such as sporotrichosis and histoplasmosis. In other cases, lesions have been originally misdiagnosed as Kaposi sarcoma, drug reactions, or varicella [
         <a href="#rid145">
          145
         </a>
         ]. IRIS-associated cutaneous manifestations of disseminated
         <em>
          E. africanus
         </em>
         infection have also been reported [
         <a href="#rid146">
          146,147
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Pneumocystis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Pneumocystis jirovecii
         </em>
         (formerly
         <em>
          Pneumocystis carinii
         </em>
         ) most commonly causes pneumonia in immunocompromised patients including those with AIDS, but extrapulmonary disease including cutaneous manifestations has been reported [
         <a href="#rid148">
          148
         </a>
         ]. Skin findings include macular, papular, polypoid, nodular, and molluscum contagiosum-like lesions [
         <a href="#rid149">
          149-151
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          PARASITIC INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, parasitic infections with cutaneous manifestations are not common in patients with HIV, with the exception of scabies, which has a worldwide distribution. (See
         <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">
          "Scabies: Epidemiology, clinical features, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Cutaneous manifestations may also be present in the setting of leishmaniasis. High
         <em>
          Leishmania
         </em>
         -HIV coinfection rates have been reported in Brazil, Ethiopia, and the state of Bihar in India [
         <a href="#rid152">
          152
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87186.html" rel="external">
          "Cutaneous leishmaniasis: Epidemiology and control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5690.html" rel="external">
          "Visceral leishmaniasis: Epidemiology and control"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Scabies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HIV, scabies can be widespread as a result of hyperinfestation, presenting as a diffuse, intensely pruritic, erythematous, papulosquamous or papulovesicular eruption (ie, crusted scabies) [
         <a href="#rid153">
          153
         </a>
         ]. Lesions typically involve the extremities, and, less commonly, the ears, face, scalp, back, buttocks, and nailfold areas [
         <a href="#rid154">
          154
         </a>
         ]. Psoriatic-like lesions with significant hyperkeratosis, a maculopapular dermatitis, an erythroderma, and red papules have also been described [
         <a href="#rid155">
          155
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">
          "Scabies: Epidemiology, clinical features, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         These highly infectious lesions contain thousands to millions of organisms and are a source for nosocomial infection [
         <a href="#rid156">
          156
         </a>
         ]. They can become secondarily infected with bacteria, leading to fever, cellulitis, and bacteremia.
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Leishmaniasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with AIDS, leishmaniasis has been reported to be the second most common tissue-associated protozoan opportunistic infection [
         <a href="#rid157">
          157,158
         </a>
         ]. Leishmaniasis can be classified geographically into New World versus Old World disease, and infections by the various species can be divided into cutaneous, diffuse cutaneous, mucocutaneous, or visceral leishmaniasis. Although some
         <em>
          Leishmania
         </em>
         species are primarily dermatotropic, while others are mainly viscerotropic, it has become increasingly clear that some species frequently associated with visceral leishmaniasis can produce skin lesions, and conversely, species usually found in the skin can disseminate viscerally. This was illustrated in a report of 32 patients with HIV and visceral leishmaniasis, six of whom had cutaneous lesions [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p>
         The cutaneous findings of leishmaniasis include macular, papular, nodular, and plaque-like lesions that can later ulcerate. Patients with HIV are at increased risk for
         <em>
          Leishmania
         </em>
         infection, and may present with more severe and atypical disease. They also have a decreased likelihood of responding to therapy, and an increased likelihood of relapse [
         <a href="#rid158">
          158
         </a>
         ]. Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome has also been reported in patients with AIDS [
         <a href="#rid160">
          160
         </a>
         ]. More detailed discussions of the dermatologic presentations associated with the various forms of leishmaniasis are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5732.html" rel="external">
          "Visceral leishmaniasis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">
          "Cutaneous leishmaniasis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          KAPOSI SARCOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kaposi sarcoma (KS) is a vascular tumor associated with infection by human herpesvirus 8 [
         <a href="#rid161">
          161
         </a>
         ], but it is rarely associated with fever. KS is described most frequently among individuals with HIV and advanced immunosuppression. However, KS can present at any CD4 count, and cases presenting soon after initiation of ART have been well recognized [
         <a href="#rid162">
          162,163
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         KS lesions do not blanch and initially appear as papular or patch-like, but later develop into plaques or nodules that can coalesce or ulcerate. The color of these lesions changes with time from light brown or pink to a darker violet, which can be confused with cutaneous
         <em>
          Bartonella
         </em>
         (see
         <a class="local">
          'Bacillary angiomatosis'
         </a>
         above). Other cutaneous variants are described as patch-like, exophytic, keloidal, telangiectatic, infiltrative, lymphangioma-like, cystic-like, bullous, lymphadenopathic, or ecchymotic [
         <a href="#rid164">
          164
         </a>
         ].
        </p>
        <p>
         Cutaneous lesions occur most commonly on the trunk  (
         <a class="graphic graphic_picture graphicRef51962" href="/z/d/graphic/51962.html" rel="external">
          picture 17
         </a>
         ), the extremities, and the face, and are often asymptomatic. Oral lesions associated with KS are classically found on the hard palate, although the tonsils, gingiva  (
         <a class="graphic graphic_picture graphicRef81245" href="/z/d/graphic/81245.html" rel="external">
          picture 18
         </a>
         ), soft palate, tongue, or lips may be involved. In addition to mucocutaneous involvement, KS can involve lymph nodes, the lungs, the gastrointestinal tract, and other visceral organs. (See
         <a class="medical medical_review" href="/z/d/html/8034.html" rel="external">
          "AIDS-related Kaposi sarcoma: Staging and treatment"
         </a>
         .)
        </p>
        <p>
         In the United States, the incidence, mortality, and morbidity of KS has declined significantly since the introduction of effective combination antiretroviral therapy (ART), and it is projected that the incidence rate will continue to decline [
         <a href="#rid165">
          165
         </a>
         ]. In fact, KS is no longer the most common HIV-associated tumor [
         <a href="#rid166">
          166
         </a>
         ]. In the era of combination ART, the most common cutaneous cancers in patients with HIV infection are non-AIDS-defining cancers, such as basal cell and squamous cell carcinomas [
         <a href="#rid167">
          167,168
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          DRUG REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug reactions, particularly cutaneous manifestations, are common in patients with HIV and appear to be directly related to the degree of immunocompromise [
         <a href="#rid3">
          3,169-172
         </a>
         ]. A morbilliform rash (74 percent) has been most frequently described (particularly with the use of nonnucleoside reverse transcriptase inhibitors), followed by urticarial eruptions (17 percent) [
         <a href="#rid3">
          3
         </a>
         ]. Fever may be a prominent part of the clinical presentation.
        </p>
        <p>
         In one review of 684 patients with HIV infection,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">
          sulfadiazine
         </a>
         , trimethoprim-dapsone, and amino penicillins were associated with the highest incidence of adverse cutaneous drug reactions [
         <a href="#rid3">
          3
         </a>
         ]. Amprenavir,
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         , and
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         are antiretroviral agents that are most commonly associated with hypersensitivity reactions [
         <a href="#rid173">
          173-175
         </a>
         ].
         <a class="drug drug_general" data-topicid="8609" href="/z/d/drug information/8609.html" rel="external">
          Enfuvirtide
         </a>
         , a fusion inhibitor, almost always results in a local injection site reaction, which includes pain/discomfort, induration, erythema, nodules/cysts, pruritus, and/or ecchymosis [
         <a href="#rid176">
          176
         </a>
         ]. Other anti-HIV agents, including integrase strand transfer inhibitors (eg, bictegravir,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ),
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">
          tipranavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">
          maraviroc
         </a>
         , have also been associated with adverse cutaneous reactions of various types [
         <a href="#rid170">
          170,177,178
         </a>
         ]. A more detailed discussion of the individual agents is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          Abacavir
         </a>
         , a nucleoside reverse transcriptase inhibitor, causes a well-described hypersensitivity reaction in approximately 5 percent of patients within six weeks of beginning this antiretroviral nucleoside reverse transcriptase inhibitor. This hypersensitivity reaction consists of rash (typically maculopapular or urticarial in appearance), fever, constitutional symptoms, respiratory symptoms, and GI complaints. Patients at risk for developing this reaction can be identified by pharmacogenetic screening for the human leukocyte antigen (HLA) HLA-B(*)5701 allele [
         <a href="#rid179">
          179,180
         </a>
         ]. Resolution of symptoms typically occurs within three days of discontinuation of the agent [
         <a href="#rid181">
          181
         </a>
         ]. Resuming abacavir therapy after the development of this drug hypersensitivity syndrome is not recommended, regardless of HLA-B(*)5701 status. (See
         <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">
          "Abacavir hypersensitivity reaction"
         </a>
         .)
        </p>
        <p>
         Severe cutaneous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) are described more frequently in patients with HIV compared to HIV-seronegative patients and are commonly associated with sulfa-based drugs [
         <a href="#rid182">
          182,183
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients"
         </a>
         .)
        </p>
        <p>
         In addition, risk for adverse cutaneous drug reactions secondary to antituberculous therapy is increased in the setting of HIV infection [
         <a href="#rid184">
          184,185
         </a>
         ].
        </p>
        <p>
         The immune reconstitution syndrome is reported in up to 25 percent of patients who begin ART [
         <a href="#rid8">
          8,9
         </a>
         ]. Cutaneous manifestations are common and can be secondary to viral, fungal, mycobacterial and parasitic infections.
        </p>
        <p class="headingAnchor" id="H30755863">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with chronic HIV infection have a defect in cell-mediated immunity that predisposes them to certain bacterial, fungal, mycobacterial, and viral infections, many of which have cutaneous findings. Rash can also occur secondary to a drug reaction, underlying Kaposi sarcoma (KS), or as a manifestation of acute HIV infection itself. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with HIV infection have an increased incidence of bacterial infections that is related to both deficiencies in T cell function and dysregulation of humoral immunity in advanced disease. One of the most common infections is
         <em>
          Staphylococcus aureus
         </em>
         , which can present as impetigo, folliculitis, cellulitis, abscesses, ulcerations, or ecthyma gangrenosum.
         <em>
          Bartonella
         </em>
         infection occurs in patients with advanced immunosuppression and usually presents with cutaneous lesions that are violaceous in appearance due to the vascular nature. Rash is the most characteristic finding in secondary syphilis, occurring in more than 80 percent of patients. (See
         <a class="local">
          'Bacterial infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rash related to herpes viruses (eg, herpes simplex virus or varicella-zoster virus) usually represents reactivation disease. Parvovirus B19 can cause fever, arthralgia, and a lacy reticular rash on the trunk and extremities in both immunocompetent and immunocompromised individuals, although patients with HIV and advanced immunosuppression are at risk for chronic anemia. (See
         <a class="local">
          'Viral infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endemic fungi must be considered in any patient with HIV, skin lesions, and systemic disease. Fungi can disseminate when cell-mediated immunity falls, either during the acute stage of infection or as a result of reactivation of prior disease. One of the most common fungal infections in patients with HIV includes cryptococcosis, which can present with a variety of cutaneous lesions including ulcers, nodules/papules, pustules, or molluscum contagiosum-like centrally umbilicated vesicular lesions. (See
         <a class="local">
          'Fungal infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, parasitic infections with cutaneous manifestations are not common in patients with HIV, with the exception of scabies, which has a worldwide distribution. Among patients with HIV, scabies can be widespread, presenting as a diffuse erythematous papulosquamous eruption. Cutaneous manifestations can also be seen in the setting of leishmaniasis. (See
         <a class="local">
          'Parasitic infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         KS may present with oral or cutaneous involvement. Papular or patch-like KS lesions later develop into plaques or nodules. The color of these lesions changes with time from light brown or pink to a darker violet. KS is a manifestation of human herpes virus-8, but is rarely associated with fever. (See
         <a class="local">
          'Kaposi sarcoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug reactions, particularly cutaneous manifestations, are common in patients with HIV and appear to be directly related to the degree of immunocompromise. Fever and a diffuse morbilliform or urticarial rashes have been reported along with fever. (See
         <a class="local">
          'Drug reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4218064728">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Uthayakumar S, Nandwani R, Drinkwater T, et al. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997; 137:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989; 125:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottschalk GM. Pediatric HIV/AIDS and the skin: an update. Dermatol Clin 2006; 24:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zancanaro PC, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006; 54:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen BL, Weismann K, Sindrup JH, et al. Incidence and prognostic significance of skin disease in patients with HIV/AIDS: a 5-year observational study. Acta Derm Venereol 2000; 80:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh BK, Chan RK, Sen P, et al. Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Int J Dermatol 2007; 46:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmige V, McNulty M, Silverman E, David MZ. Predictors of skin and soft tissue infections in HIV-infected outpatients in the community-associated methicillin-resistant Staphylococcus aureus era. Eur J Clin Microbiol Infect Dis 2015; 34:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan E, Hohmann S, Ridgway JP, et al. Decreasing Incidence of Skin and Soft-tissue Infections in 86 US Emergency Departments, 2009-2014. Clin Infect Dis 2019; 68:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med 1988; 85:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller M, Cespedes C, Vavagiakis P, et al. Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. Eur J Clin Microbiol Infect Dis 2003; 22:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bär A, Hantschke D, Mirmohammadsadegh A, Hengge UR. Spectrum of bacterial isolates in HIV-positive patients with skin and soft tissue infections: emergence of methicillin-resistant Staphylococci. AIDS 2003; 17:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melles DC, Pauw E, van den Boogaard L, et al. Host-microbe interplay in persistent Staphylococcus aureus nasal carriage in HIV patients. Microbes Infect 2008; 10:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popovich KJ, Hota B, Aroutcheva A, et al. Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients. Clin Infect Dis 2013; 56:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skiest D, Brown K, Hester J, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med 2006; 7:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cenizal MJ, Hardy RD, Anderson M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr 2008; 48:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med 2008; 121:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr 2005; 40:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum-Cianflone NF, Shadyab AH, Weintrob A, et al. Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV). Medicine (Baltimore) 2011; 90:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zervou FN, Zacharioudakis IM, Ziakas PD, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis. Clin Infect Dis 2014; 59:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popovich KJ, Weinstein RA, Aroutcheva A, et al. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis 2010; 50:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med 2012; 13:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmige V, McNulty M, Silverman E, David MZ. Recurrent skin and soft tissue infections in HIV-infected patients during a 5-year period: incidence and risk factors in a retrospective cohort study. BMC Infect Dis 2015; 15:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreisel K, Boyd K, Langenberg P, Roghmann MC. Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia. Diagn Microbiol Infect Dis 2006; 55:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson JW, Kitces EN, Neafie RC. Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol 1987; 16:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahdoot D, Rickman LS, Haghighi P, Heard WU. Botryomycosis in the acquired immunodeficiency syndrome. Cutis 1995; 55:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrascosa JM, Ribera M, Bielsa I, et al. Bacillary angiomatosis presenting as a malleolar ulcer. Arch Dermatol 1995; 131:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koehler JE, Sanchez MA, Tye S, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis 2003; 37:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blocker ME, Levine WC, St Louis ME. HIV prevalence in patients with syphilis, United States. Sex Transm Dis 2000; 27:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zetola NM, Bernstein KT, Wong E, et al. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr 2009; 50:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Courjon J, Hubiche T, Dupin N, et al. Clinical Aspects of Syphilis Reinfection in HIV-Infected Patients. Dermatology 2015; 230:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenyon C, Osbak KK, Apers L. Repeat Syphilis Is More Likely to Be Asymptomatic in HIV-Infected Individuals: A Retrospective Cohort Analysis With Important Implications for Screening. Open Forum Infect Dis 2018; 5:ofy096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zetola NM, Klausner JD. Syphilis and HIV infection: an update. Clin Infect Dis 2007; 44:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farhi D, Dupin N. Management of syphilis in the HIV-infected patient: facts and controversies. Clin Dermatol 2010; 28:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell D, Polgreen PM, Beekmann SE, et al. Dilemmas in the management of syphilis: a survey of infectious diseases experts. Clin Infect Dis 2009; 49:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rompalo AM, Joesoef MR, O'Donnell JA, et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis 2001; 28:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sands M, Markus A. Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review. Clin Infect Dis 1995; 20:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson CM, Hook EW 3rd, Shepherd M, et al. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med 1994; 121:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rompalo AM, Lawlor J, Seaman P, et al. Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. Sex Transm Dis 2001; 28:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collis TK, Celum CL. The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men. Clin Infect Dis 2001; 32:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankel RE, Virata M, Hardalo C, et al. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996; 23:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordano Q, Falcó V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Lechuz JM, Cuevas O, Castellares C, et al. Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis 2007; 26:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez Barradas MC, Musher DM, Hamill RJ, et al. Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited. Clin Infect Dis 1992; 14:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capdevila O, Grau I, Vadillo M, et al. Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis 2003; 22:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesourd A, Leporrier J, Delbos V, et al. Antiretroviral Therapy as Prevention of … Pneumococcal Infections? Open Forum Infect Dis 2016; 3:ofw228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiehlbauch JA, Tauxe RV, Baker CN, Wachsmuth IK. Helicobacter cinaedi-associated bacteremia and cellulitis in immunocompromised patients. Ann Intern Med 1994; 121:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burman WJ, Cohn DL, Reves RR, Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis 1995; 20:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimizu S, Shimizu H. Cutaneous manifestations of Helicobacter cinaedi: a review. Br J Dermatol 2016; 175:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morel F, Brossier F, Mbadi A, et al. Helicobacter cinaedi bacteraemia in an HIV-infected patient. Med Mal Infect 2015; 45:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terranova M, Padovese V, Fornari U, Morrone A. Clinical and epidemiological study of cutaneous tuberculosis in Northern Ethiopia. Dermatology 2008; 217:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daikos GL, Uttamchandani RB, Tuda C, et al. Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases. Clin Infect Dis 1998; 27:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antinori S, Bini T, Galimberti L, et al. Cutaneous miliary tuberculosis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:1484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montejo M, Goicoetxea J, Agesta N, et al. Cutaneous infection by Mycobacterium lentiflavum in a patient with HIV. Dermatology 2006; 213:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           High WA, Evans CC, Hoang MP. Cutaneous miliary tuberculosis in two patients with HIV infection. J Am Acad Dermatol 2004; 50:S110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor CR, Bailey EM. Red nodule on the forearm of an HIV-positive man. Isolated cutaneous Mycobacterium avium-intracellulare infection. Arch Dermatol 1998; 134:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown T, Yen A. Isolation of Mycobacterium avium complex from erythema multiforme. J Am Acad Dermatol 1998; 39:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nomura Y, Nishie W, Shibaki A, et al. Disseminated cutaneous Mycobacterium kansasii infection in an patient infected with the human immunodeficiency virus. Clin Exp Dermatol 2009; 34:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saubolle MA, Kiehn TE, White MH, et al. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 1996; 9:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fariña MC, Gegundez MI, Piqué E, et al. Cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study. J Am Acad Dermatol 1995; 33:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanelli G, Webster GF. Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Clin Dermatol 1995; 13:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groves R. Unusual cutaneous mycobacterial diseases. Clin Dermatol 1995; 13:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valenti WM. Acute retroviral syndrome: a challenge for primary care. AIDS Read 2008; 18:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis 2004; 38:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapins J, Gaines H, Lindbäck S, et al. Skin and mucosal characteristics of symptomatic primary HIV-1 infection. AIDS Patient Care STDS 1997; 11:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese LH, Proffitt MR, Levin KH, et al. Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. Ann Intern Med 1987; 107:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macneal RJ, Dinulos JG. Acute retroviral syndrome. Dermatol Clin 2006; 24:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg ES, Caliendo AM, Walker BD. Acute HIV infection among patients tested for mononucleosis. N Engl J Med 1999; 340:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celum CL. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004; 11 Suppl 1:36A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosunjac M, Park J, Wang W, et al. Genital and perianal herpes simplex simulating neoplasia in patients with AIDS. AIDS Patient Care STDS 2009; 23:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JM, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown EL, Wald A, Hughes JP, et al. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol 2006; 164:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong MA, de Witte L, Taylor ME, Geijtenbeek TB. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol 2010; 185:1633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnabas RV, Wasserheit JN, Huang Y, et al. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 2011; 57:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis 2020; 20:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tappero JW, Perkins BA, Wenger JD, Berger TG. Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev 1995; 8:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colebunders R, Mann JM, Francis H, et al. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis 1988; 157:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 2015; 60:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez E, Gatell J, Morán Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27:1510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001; 110:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol 2012; 66:e217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikkels AF, Snoeck R, Rentier B, Pierard GE. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin Exp Dermatol 1999; 24:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppenjans WB, Bibler MR, Orme RL, Solinger AM. Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome. Arch Dermatol 1990; 126:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli C, Azzi A, Buffini G, et al. Cutaneous vasculitis due to human parvovirus B19 in an HIV-infected patient: report of a case. AIDS 1997; 11:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke J, Lee JD. Primary human parvovirus B19 infection in an HIV infected patient on highly active antiretroviral therapy. Sex Transm Infect 2003; 79:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morelli P, Bestetti G, Longhi E, et al. Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature. Eur J Clin Microbiol Infect Dis 2007; 26:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts H, Jiles R, Harris AM, et al. Incidence and Prevalence of Sexually Transmitted Hepatitis B, United States, 2013-2018. Sex Transm Dis 2021; 48:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minamoto GY, Rosenberg AS. Fungal infections in patients with acquired immunodeficiency syndrome. Med Clin North Am 1997; 81:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RA. HIV disease: mucocutaneous fungal infections in HIV disease. Clin Dermatol 2000; 18:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clin Infect Dis 2007; 45:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-e-Silva M, Lima CM, Schechtman RC, et al. Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol 2012; 30:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers SA, Kamino H. Cutaneous cryptococcosis and histoplasmosis coinfection in a patient with AIDS. J Am Acad Dermatol 1996; 34:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aftergut K, Cockerell CJ. Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. Dermatol Clin 1999; 17:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakawa GJ, Kerschmann R, Berger T. Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Arch Dermatol 1996; 132:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler B, Potter TS, Hashimoto K. Cutaneous Pneumocystis carinii and Cryptococcus neoformans in AIDS. Br J Dermatol 1996; 134:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005; 51:e289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fredricks DN, Rojanasthien N, Jacobson MA. AIDS-related disseminated histoplasmosis in San Francisco, California. West J Med 1997; 167:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobón AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg 2005; 73:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dover JS, Johnson RA. Cutaneous manifestations of human immunodeficiency virus infection. Part II. Arch Dermatol 1991; 127:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson PC, Khardori N, Najjar AF, et al. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laochumroonvorapong P, DiCostanzo DP, Wu H, et al. Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. Int J Dermatol 2001; 40:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           K Ramdial P, Mosam A, Dlova NC, et al. Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus. J Cutan Pathol 2002; 29:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahy S, Bel B, Chavanet P, et al. Disseminated histoplasmosis with cutaneous lesions in an HIV patient. Eur J Dermatol 2011; 21:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzig RS, Hoadley DJ, Greer DL, et al. Blastomycosis and human immunodeficiency virus: three new cases and review. South Med J 1994; 87:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993; 94:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010; 50:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prichard JG, Sorotzkin RA, James RE 3rd. Cutaneous manifestations of disseminated coccidioidomycosis in the acquired immunodeficiency syndrome. Cutis 1987; 39:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mu A, Shein TT, Jayachandran P, Paul S. Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature. J Int Assoc Provid AIDS Care 2017; 16:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware AJ, Cockerell CJ, Skiest DJ, Kussman HM. Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS. J Am Acad Dermatol 1999; 40:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis 1998; 26:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freitas DF, de Siqueira Hoagland B, do Valle AC, et al. Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2012; 50:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez-Galhardo MC, do Valle AC, Fraga BL, et al. Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndrome. Mycoses 2010; 53:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borradori L, Schmit JC, Stetzkowski M, et al. Penicilliosis marneffei infection in AIDS. J Am Acad Dermatol 1994; 31:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ying RS, Le T, Cai WP, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017. HIV Med 2020; 21:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ungpakorn R. Cutaneous manifestations of Penicillium marneffei infection. Curr Opin Infect Dis 2000; 13:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis 2011; 52:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annam V, Inamadar AC, Palit A, et al. Genital ulcer caused by Penicillium marneffei in an HIV-infected patient. Sex Transm Infect 2007; 83:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong AC, Wong M, Smith NJ. Penicillium marneffei infection presenting as oral ulcerations in a patient infected with human immunodeficiency virus. J Oral Maxillofac Surg 2001; 59:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall C, Hajjawi R, Barlow G, et al. Penicillium marneffei presenting as an immune reconstitution inflammatory syndrome (IRIS) in a patient with advanced HIV. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thanh NT, Vinh LD, Liem NT, et al. Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated with Talaromyces marneffei infection. Med Mycol Case Rep 2018; 19:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson M, Nguyen LH, Wertheim HF, et al. Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam. AIDS Res Ther 2012; 9:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenyon C, Bonorchis K, Corcoran C, et al. A dimorphic fungus causing disseminated infection in South Africa. N Engl J Med 2013; 369:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maphanga TG, Britz E, Zulu TG, et al. In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients. J Clin Microbiol 2017; 55:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz IS, Govender NP, Corcoran C, et al. Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. Clin Infect Dis 2015; 61:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crombie K, Spengane Z, Locketz M, et al. Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy. PLoS Negl Trop Dis 2018; 12:e0006173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz IS, Kenyon C, Lehloenya R, et al. AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. Open Forum Infect Dis 2017; 4:ofx186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulman CU, Greene I, Archibald RW. Cutaneous pneumocystosis. Ann Intern Med 1987; 106:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennessey NP, Parro EL, Cockerell CJ. Cutaneous Pneumocystis carinii infection in patients with acquired immunodeficiency syndrome. Arch Dermatol 1991; 127:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praveen CV, Terry RM, Elmahallawy M, Horsfield C. Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient. J Laryngol Otol 2002; 116:288.
          </a>
         </li>
         <li class="breakAll">
          The World Health Organization. Leishmaniasis fact sheet. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (Accessed on January 04, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guggisberg D, de Viragh PA, Constantin C, Panizzon RG. Norwegian scabies in a patient with acquired immunodeficiency syndrome. Dermatology 1998; 197:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perna AG, Bell K, Rosen T. Localised genital Norwegian scabies in an AIDS patient. Sex Transm Infect 2004; 80:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlesinger I, Oelrich DM, Tyring SK. Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. South Med J 1994; 87:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone PA. Scabies and pediculosis pubis: an update of treatment regimens and general review. Clin Infect Dis 2007; 44 Suppl 3:S153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis 2007; 45:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postigo C, Llamas R, Zarco C, et al. Cutaneous lesions in patients with visceral leishmaniasis and HIV infection. J Infect 1997; 35:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha S, Fernández G, Kapila R, et al. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacombe JM, Boue F, Grabar S, et al. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. AIDS 2013; 27:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiels MS, Islam JY, Rosenberg PS, et al. Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030. Ann Intern Med 2018; 168:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum-Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV-infected persons. Arch Intern Med 2009; 169:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AY, Doiron P, Maurer T. Cutaneous malignancies in HIV. Curr Opin HIV AIDS 2017; 12:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern RS. Epidemiology of skin disease in HIV infection: a cohort study of health maintenance organization members. J Invest Dermatol 1994; 102:34S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 2008; 62:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 2010; 63:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol 2010; 63:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 2002; 46:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol 2008; 121:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luther J, Glesby MJ. Dermatologic adverse effects of antiretroviral therapy: recognition and management. Am J Clin Dermatol 2007; 8:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis L, Nichols G, Stainsby C, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials 2014; 15:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loulergue P, Mir O. Raltegravir-induced DRESS syndrome. Scand J Infect Dis 2012; 44:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008; 42:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991; 127:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis 2011; 15:1649.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3703 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9390338" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2522293" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8487826" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cutaneous disease and drug reactions in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010781" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pediatric HIV/AIDS and the skin: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16546578" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10877138" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence and prognostic significance of skin disease in patients with HIV/AIDS: a 5-year observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17614796" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16392092" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22233655" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Immune reconstitution inflammatory syndrome: incidence and implications for mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25213720" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Predictors of skin and soft tissue infections in HIV-infected outpatients in the community-associated methicillin-resistant Staphylococcus aureus era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29912305" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Decreasing Incidence of Skin and Soft-tissue Infections in 86 US Emergency Departments, 2009-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3400693" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12884066" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12819529" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Spectrum of bacterial isolates in HIV-positive patients with skin and soft tissue infections: emergence of methicillin-resistant Staphylococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983910" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18248760" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Host-microbe interplay in persistent Staphylococcus aureus nasal carriage in HIV patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23325428" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16903980" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645516" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18374690" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The risk of infection after nasal colonization with Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16186732" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22033452" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25031291" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20192731" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22276696" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26503616" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Recurrent skin and soft tissue infections in HIV-infected patients during a 5-year period: incidence and risk factors in a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16631340" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3819060" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634844" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Botryomycosis in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7632077" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bacillary angiomatosis presenting as a malleolar ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12905141" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10654870" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : HIV prevalence in patients with syphilis, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19367993" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25823442" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical Aspects of Syphilis Reinfection in HIV-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29977956" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Repeat Syphilis Is More Likely to Be Asymptomatic in HIV-Infected Individuals: A Retrospective Cohort Analysis With Important Implications for Screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407043" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Syphilis and HIV infection: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20797515" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of syphilis in the HIV-infected patient: facts and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19845476" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dilemmas in the management of syphilis: a survey of infectious diseases experts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11289198" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742445" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912483" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11473216" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Modification of syphilitic genital ulcer manifestations by coexistent HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181126" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1637028" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8879783" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156452" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17197876" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : HIV and pneumococcal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372776" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571428" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12783279" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009870" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28018929" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antiretroviral Therapy as Prevention of…Pneumococcal Infections?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389249" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017741" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Helicobacter cinaedi-associated bacteremia and cellulitis in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756476" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26678698" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cutaneous manifestations of Helicobacter cinaedi: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25623629" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Helicobacter cinaedi bacteraemia in an HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18446032" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical and epidemiological study of cutaneous tuberculosis in Northern Ethiopia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9675477" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9431410" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Cutaneous miliary tuberculosis in a patient infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16902301" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cutaneous infection by Mycobacterium lentiflavum in a patient with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15097943" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cutaneous miliary tuberculosis in two patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9801686" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Red nodule on the forearm of an HIV-positive man. Isolated cutaneous Mycobacterium avium-intracellulare infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738789" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Isolation of Mycobacterium avium complex from erythema multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19236419" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Disseminated cutaneous Mycobacterium kansasii infection in an patient infected with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8894345" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7657867" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8521371" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8521367" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Unusual cutaneous mycobacterial diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488505" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16231262" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18623891" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Acute retroviral syndrome: a challenge for primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11187417" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156484" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary HIV type 1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11361765" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Skin and mucosal characteristics of symptomatic primary HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3688679" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010773" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Acute retroviral syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10094651" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Acute HIV infection among patients tested for mononucleosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15115628" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The interaction between herpes simplex virus and human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19302018" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Genital and perianal herpes simplex simulating neoplasia in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630545" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896053" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327322" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20592277" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21860356" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31753763" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1308664" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Herpes zoster and human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7553576" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3335810" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8519451" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Herpes zoster, immunological deterioration and disease progression in HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562746" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601456" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9868668" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11382367" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21056516" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10564318" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2166483" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9412714" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Cutaneous vasculitis due to human parvovirus B19 in an HIV-infected patient: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12902591" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Primary human parvovirus B19 infection in an HIV infected patient on highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17674060" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33492099" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Incidence and Prevalence of Sexually Transmitted Hepatitis B, United States, 2013-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093234" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Fungal infections in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11024308" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : HIV disease: mucocutaneous fungal infections in HIV disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17918087" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23068149" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Systemic mycoses in immunodepressed patients (AIDS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621824" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Cutaneous cryptococcosis and histoplasmosis coinfection in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10410852" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8624151" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8745906" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Cutaneous Pneumocystis carinii and Cryptococcus neoformans in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16321643" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9392979" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : AIDS-related disseminated histoplasmosis in San Francisco, California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16172484" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929464" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Cutaneous manifestations of human immunodeficiency virus infection. Part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3400691" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11703524" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028154" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21245021" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Disseminated histoplasmosis with cutaneous lesions in an HIV patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327328" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1567099" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Blastomycosis in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8023204" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Blastomycosis and human immunodeficiency virus: three new cases and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8095771" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706825" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Coccidioidomycosis among persons with AIDS in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19995218" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3829728" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Cutaneous manifestations of disseminated coccidioidomycosis in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28911256" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025867" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9636870" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21859385" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476718" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19019165" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962732" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Penicilliosis marneffei infection in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8816141" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33369035" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11964779" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Cutaneous manifestations of Penicillium marneffei infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21427403" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17569724" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Genital ulcer caused by Penicillium marneffei in an HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11474465" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Penicillium marneffei infection presenting as oral ulcerations in a patient infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23362074" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Penicillium marneffei presenting as an immune reconstitution inflammatory syndrome (IRIS) in a patient with advanced HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29379703" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated with Talaromyces marneffei infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912350" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Disseminated Penicillium marneffei infection in southeast Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12423616" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22897817" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24106934" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : A dimorphic fungus causing disseminated infection in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28356416" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26060283" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29518092" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29164168" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9227859" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Extrapulmonary pneumocystosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3492951" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Cutaneous pneumocystosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1952976" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Cutaneous Pneumocystis carinii infection in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11945191" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11945191" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9812044" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Norwegian scabies in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14755042" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Localised genital Norwegian scabies in an AIDS patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8134858" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17342668" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Scabies and pediculosis pubis: an update of treatment regimens and general review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17918086" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400800" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : The relationship between leishmaniasis and AIDS: the second 10 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9459400" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Cutaneous lesions in patients with visceral leishmaniasis and HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19126013" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039116" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : KSHV infection and the pathogenesis of Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051964" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23196937" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15334644" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Kaposi's sarcoma: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29801099" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17565153" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : AIDS-related cancer and severity of immunosuppression in persons with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546414" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Cutaneous malignancies among HIV-infected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27875372" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Cutaneous malignancies in HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8006432" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Epidemiology of skin disease in HIV infection: a cohort study of health maintenance organization members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18653488" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20846563" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20846564" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11052597" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Adverse effects of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11807442" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Cutaneous manifestations of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18190954" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Diagnosis and management of HIV drug hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17645377" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Dermatologic adverse effects of antiretroviral therapy: recognition and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25350958" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22803794" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Raltegravir-induced DRESS syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18303141" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Abacavir hypersensitivity reaction: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256392" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : HLA-B*5701 screening for hypersensitivity to abacavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317695" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1827245" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8691227" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12569078" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22118173" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
